

# Accepted Manuscript



Pacing across the membrane: the novel PACE family of efflux pumps is widespread in Gram-negative pathogens

Karl A. Hassan, Qi Liu, Liam D.H. Elbourne, Irshad Ahmad, David Sharples, Varsha Naidu, Chak Lam Chan, Liping Li, Steven P.D. Harborne, Alaska Pokhrel, Vincent L.G. Postis, Adrian Goldman, Peter J.F. Henderson, Ian T. Paulsen

PII: S0923-2508(18)30009-3

DOI: [10.1016/j.resmic.2018.01.001](https://doi.org/10.1016/j.resmic.2018.01.001)

Reference: RESMIC 3636

To appear in: *Research in Microbiology*

Received Date: 5 September 2017

Revised Date: 27 November 2017

Accepted Date: 8 January 2018

Please cite this article as: K.A. Hassan, Q. Liu, L.D.H. Elbourne, I. Ahmad, D. Sharples, V. Naidu, C.L. Chan, L. Li, S.P.D. Harborne, A. Pokhrel, V.L.G. Postis, A. Goldman, P.J.F. Henderson, I.T. Paulsen, Pacing across the membrane: the novel PACE family of efflux pumps is widespread in Gram-negative pathogens, *Research in Microbiologoy* (2018), doi: 10.1016/j.resmic.2018.01.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**For publication****Pacing across the membrane: the novel PACE family of efflux pumps is  
widespread in Gram-negative pathogens**

Karl A. Hassan<sup>a,b,c\*</sup>, Qi Liu<sup>c</sup>, Liam D.H. Elbourne<sup>c</sup>, Irshad Ahmad<sup>b</sup>, David Sharples<sup>b</sup>, Varsha Naidu<sup>c</sup>, Chak Lam Chan<sup>b</sup>, Liping Li<sup>c</sup>, Steven P.D. Harborne<sup>b</sup>, Alaska Pokhrel<sup>c</sup>, Vincent L.G. Postis<sup>b,d</sup>, Adrian Goldman<sup>b,e</sup>, Peter J.F. Henderson<sup>b</sup>, Ian T. Paulsen<sup>c</sup>

<sup>a</sup>*School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW, Australia*

<sup>b</sup>*School of BioMedical Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, UK*

<sup>c</sup>*Department of Chemistry and Biomolecular Science, Macquarie University, North Ryde, NSW, Australia*

<sup>d</sup>*Biomedicine Research Group, Faculty of Health and Social Sciences, Leeds Beckett University, Leeds, UK*

<sup>e</sup>*Division of Biochemistry, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland*

\*Address correspondence to: Karl A. Hassan, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW, 2308, Australia. Karl.Hassan@newcastle.edu.au.

**21 Abstract**

22       The proteobacterial antimicrobial compound efflux (PACE) family of transport  
23 proteins was only recently described. PACE family transport proteins can confer resistance to  
24 a range of biocides used as disinfectants and antiseptics, and are encoded by many important  
25 Gram-negative human pathogens. However, we are only just beginning to appreciate the  
26 range of functions and the mechanism(s) of transport operating in these proteins. Genes  
27 encoding PACE family proteins are typically conserved in the core genomes of bacterial  
28 species rather than on recently acquired mobile genetic elements, suggesting that they confer  
29 important core functions in addition to biocide resistance. Three-dimensional structural  
30 information is not yet available for PACE family proteins. However, PACE proteins have  
31 several very highly conserved amino acid sequence motifs that are likely to be important for  
32 substrate transport. PACE proteins also display strong amino acid sequence conservation  
33 between their N- and C-terminal halves, suggesting that they evolved by duplication of an  
34 ancestral protein comprised of two transmembrane helices. In light of their drug resistance  
35 functions in Gram-negative pathogens, PACE proteins should be the subject of detailed future  
36 investigation.

37

38 *Keywords:* Membrane transport; Gram-negative pathogen; Antimicrobial resistance; Efflux,  
39 PACE; Bacterial transmembrane pair domain

40

## 41 **1.Introduction**

42 In the broadest sense, drug resistance may arise in actively growing bacterial cells in  
43 two distinct ways: either the drug target site is protected from the toxic activities of the drug  
44 by modification or bypass, or the drug cannot reach the target site due to degradation,  
45 sequestration, reduced cellular entry or active efflux. Efflux is a major mechanism of drug  
46 resistance, and due to the high promiscuity in substrate recognition by the transport proteins  
47 involved, efflux-mediated resistance is found for a wide range of different antimicrobial  
48 compounds.

49 Drug efflux proteins from five distinct families of transport proteins were described  
50 between the 1970s and 2000, and have been studied extensively at both the functional and  
51 structural levels [1]. These families include the ATP-binding cassette (ABC) superfamily, the  
52 major facilitator superfamily (MFS), the resistance-nodulation-cell division (RND)  
53 superfamily, the multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) flippase superfamily  
54 and the drug/metabolite transporter (DMT) superfamily. In the last five years two new  
55 transporter families that include bacterial drug efflux systems have been identified; these are  
56 the proteobacterial antimicrobial compound efflux (PACE) family and the p-aminobenzoyl-  
57 glutamate transporter (AbgT) family [2-4]. Proteins from the PACE family transport biocides  
58 such as chlorhexidine and acriflavine, whereas AbgT family transporters transport  
59 sulphonamides.

## 60 **2.The *Acinetobacter baumannii* AceI protein is a prototype for the novel PACE family of** 61 **transport proteins**

62 Drug efflux systems, and drug resistance factors in general, are frequently controlled  
63 by regulators that sense the transported drug substrates or their downstream effects in the cell.  
64 For example, TetR controls expression of the *tetB* tetracycline transporter gene in response to  
65 tetracyclines, and QacR controls expression of the multidrug efflux pump gene *qacA* in

66 response to cationic antimicrobials [5]. For bacterial cells, this regulatory control means that  
67 efflux pump gene expression will proceed only when the pumps are required, saving cellular  
68 resources and preventing the potential toxic effects of constitutive high-level efflux pump  
69 expression [6]. From a research perspective, this tight regulatory control of drug efflux pump  
70 genes means that transcriptional changes may be used to identify either efflux pumps that  
71 might recognise substrates of interest, or novel factors that may be involved in drug resistance  
72 or tolerance.

73 The *Acinetobacter* chlorhexidine efflux protein (AceI) was identified by analysing the  
74 transcriptomic response of *Acinetobacter baumannii* to the membrane active biocide  
75 chlorhexidine [2, 7]. *A. baumannii* has recently emerged as major cause of Gram-negative  
76 infections in hospitals. Strains of *A. baumannii* are becoming increasingly resistant to  
77 antibiotics. Consequently, carbapenem-resistant strains of *A. baumannii* are listed as “Priority  
78 1: CRITICAL” targets for development of new antibiotics World Health Organisation [8].  
79 Chlorhexidine is listed as an essential medicine by the World Health Organisation, and is  
80 commonly used as an antiseptic in wound dressings, hand washes and mouthwashes. The  
81 transcriptome of *A. baumannii* ATCC 17978 cells exposed to a subinhibitory concentration of  
82 chlorhexidine, equivalent to half the minimum inhibitory concentration, was compared to  
83 control cells. The major gene expression changes were to genes encoding the AdeAB  
84 components of the AdeABC multidrug efflux pump and a gene annotated as encoding a  
85 hypothetical protein, A1S\_2063 [2].

86 From its sequence, the A1S\_2063 gene was predicted to encode an inner membrane  
87 protein with four transmembrane helices (Fig. 1A). The gene was cloned into an *Escherichia*  
88 *coli* expression vector and was shown to confer significant levels of resistance to  
89 chlorhexidine when overexpressed in *E. coli*. Deletion of the A1S\_2063 gene in *A. baumannii*  
90 ATCC 17978 and its ortholog in *Acinetobacter baylyi* ADP1 halved the chlorhexidine

91 resistance in the host strain, demonstrating that the genes had a resistance function in native  
92 hosts [2, 9]. The Biolog Phenotype Microarray system was used to screen over 200 additional  
93 antimicrobials against A1S\_2063 expressing *E. coli*. This analysis demonstrated no  
94 significant hits apart from chlorhexidine, suggesting that chlorhexidine had an apparent  
95 specificity as a substrate [2].

96 When overexpressed in *E. coli*, the A1S\_2063 protein was identified in the inner  
97 membrane. The protein could be readily extracted from the membrane by detergent  
98 solubilisation and purified. The detergent-solubilised protein bound to chlorhexidine with  
99 high affinity ( $K_d$  in the low  $\mu\text{M}$  range) as determined by tryptophan fluorescence quenching  
100 and near-UV synchrotron radiation circular dichroism [2]. Transport experiments using [ $^{14}\text{C}$ ]-  
101 chlorhexidine demonstrated that the A1S\_2063 protein prevented the high-level accumulation  
102 of chlorhexidine when expressed in *E. coli* until the proton-motive-force across the membrane  
103 was collapsed using a protonophore. The protein could also mediate the efflux of  
104 chlorhexidine from *E. coli* cells preloaded with chlorhexidine [2]. Together, these results  
105 suggested that the A1S\_2063 protein was a novel chlorhexidine efflux protein and that  
106 transport is likely to be proton-coupled. The protein was named AceI (*Acinetobacter*  
107 *chlorhexidine efflux protein I*).

### 108 **3.PACE proteins are a family of multidrug efflux systems conserved across many Gram-** 109 **negative pathogens**

110 Genes encoding proteins homologous to AceI are found in the genomes of many  
111 bacterial species, including pathogens such as *Pseudomonas*, *Klebsiella*, *Enterobacter*,  
112 *Salmonella* and *Burkholderia* species. These genes are particularly common among  
113 Proteobacteria, but can be found in some Actinobacteria and in a limited number of other  
114 unrelated bacterial species. To determine whether, like AceI, these proteins can mediate  
115 chlorhexidine resistance, more than 20 phylogenetically diverse homologs were cloned into

116 an *E. coli* expression system and examined by routine minimum inhibitory concentration  
117 analyses. Most of the cloned proteins were expressed at detectable levels, and about half  
118 could confer resistance to chlorhexidine [3]. Notably, at least two of the *aceI* homologs found  
119 to confer chlorhexidine resistance are also highly expressed in their native hosts,  
120 *Pseudomonas aeruginosa* and *Burkholderia cenocepacia*, in response to a chlorhexidine  
121 treatment [10, 11].

122 Additional resistance tests were performed to determine whether the antimicrobial  
123 recognition profiles of these homologs might extend beyond chlorhexidine. Many of the  
124 proteins were able to confer resistance to several additional biocides, including acriflavine,  
125 proflavine, benzalkonium and dequalinium [3]. The substrate profile of one pump, VP1155  
126 encoded by *Vibrio parahaemolyticus*, was investigated using the Biolog phenotype  
127 microarray system. In addition to chlorhexidine, benzalkonium, proflavine and acriflavine,  
128 VP1155 appeared to confer resistance to 9-aminoacridine, domiphen bromide, guanazole and  
129 plumbagin [3].

130 The demonstration that many AceI homologs are able to confer resistance to  
131 compounds such as proflavine and acriflavine presented the possibility of assaying transport  
132 by measuring their fluorescence in real time [12]. These compounds intercalate into nucleic  
133 acids, which leads to a quenching of their fluorescence. This property facilitates a convenient  
134 assay for their transport in cells expressing an efflux pump [13]. Cells expressing the protein  
135 of interest can be loaded with proflavine or acriflavine in the presence of a protonophore, such  
136 as carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), then washed and re-energised by the  
137 addition of an energy source such as D-glucose. Fluorescence can be monitored before and  
138 after energisation to examine transport [12]. These transport experiments have been  
139 performed for a number of AceI homologs and identified proteins that mediate transport of  
140 these compounds. For example, the *B. cenocepacia* HI2424 homolog Bcen2424\_2356 is able

141 to transport acriflavine, whereas at least one other homolog encoded by this strain,  
142 Bcen2424\_5347, does not (Fig. 2). Bcen2424\_2356 has been previously shown to confer  
143 resistance to chlorhexidine, benzalkonium, proflavine and acriflavine. The Biolog phenotype  
144 microarray antimicrobial resistance tests confirmed several of these phenotypes and suggested  
145 that Bcen2424\_2356 also confers resistance to benzethonium, 9-aminoacridine, methyl  
146 viologen, guanazole and plumbagin (Supplemental Fig. S2).

147 The observation that several AceI homologs can confer resistance to multiple biocides  
148 and can mediate transport of the fluorescent substrates proflavine and acriflavine led to their  
149 designation as a new family of efflux pumps. This family was called the Proteobacterial  
150 Antimicrobial Compound Efflux (PACE) family, due to their abundance in Proteobacteria [3].  
151 To date at least ten putative substrates have been identified for PACE family proteins (Fig.  
152 S3). Proteins from this family have been incorporated into the Transporter Classification  
153 Database [14] under the original family title, the proteobacterial chlorhexidine efflux (CHX)  
154 family (TCDB number: 2.A.117), and are captured in the TransportDB 2.0 database [15],  
155 which catalogues all putative transport proteins from sequenced genomes in the NCBI RefSeq  
156 database.

#### 157 **4. Predicted topology and sequence conservation in PACE pumps**

158 All PACE family proteins analysed to date are predicted to contain four  
159 transmembrane  $\alpha$ -helices, organised into two tandem bacterial transmembrane pair (BTP)  
160 domains (Fig. 1; pfam: PF05232) [16]. Given their small size, it seems very likely that PACE  
161 proteins function as oligomers. However, the oligomeric state of PACE family proteins  
162 remains unresolved. Several PACE family proteins have been experimentally characterised by  
163 overexpression and purification (Henderson et al., unpublished). When expressed in *E. coli*,  
164 these proteins localise to the inner membrane and can be readily purified by extraction with a  
165 mild detergent such as n-dodecyl- $\beta$ -D-maltoside [2], or using a styrene maleic acid co-



166 polymer (Supplemental Fig. S4) [17]. Analysis of the purified detergent-solubilised proteins  
167 by far-UV circular dichroism has confirmed their high  $\alpha$ -helical content and demonstrated  
168 that they typically show structural stability to around 50-60 °C [2].

169 A high level of amino acid sequence conservation is apparent between members of the  
170 PACE family. Based on an alignment of 47 diverse PACE family proteins from a variety of  
171 bacterial genera (Supplemental Fig. S1), four amino acid residues appear to be universally  
172 conserved across these proteins: a glutamic acid residue within transmembrane helix 1, an  
173 asparagine residue in transmembrane helix 2, an alanine residue at the periplasmic membrane  
174 boundary of transmembrane helix 4 and an aspartic acid residue at the cytoplasmic membrane  
175 boundary of transmembrane helix 4 (Fig. 1A). The functional importance of the conserved  
176 asparagine, alanine and aspartic acid residues has not yet been investigated, but neutralisation  
177 of the glutamic acid residue in the prototypical PACE family member AceI by substitution  
178 with a glutamine abolished chlorhexidine resistance and transport [2]. This mutant (E15Q)  
179 was still able to bind chlorhexidine with only slightly reduced affinity compared to the  
180 parental protein. Furthermore, the mutant protein was less thermostable than the parental  
181 protein in the absence of chlorhexidine, but was significantly more stable than the parental  
182 protein in the presence of a molar excess of chlorhexidine, supporting a binding interaction.  
183 These results suggest that the glutamic acid residue is not required for substrate binding. The  
184 high conservation of this residue in PACE proteins that have different substrate specificities  
185 suggests that it may be involved in an aspect of transport common to these proteins, such as  
186 an energy coupling reaction. The position of this residue within the transmembrane region is  
187 consistent with this possibility. In other efflux pumps from the MFS, SMR and MATE  
188 families, membrane embedded carboxyl residues participate in coupling reactions [18-20].

189 PACE family proteins contain several highly conserved amino acid residues in  
190 addition to the four universally conserved residues. The amino acid sequence conservation is

191 particularly strong close to the predicted cytoplasmic boundaries of the transmembrane  
192 helices, where four amino acid sequence motifs have been identified (Fig. 1). In line with the  
193 PACE proteins containing tandem BTP domains, the amino acid sequence motif in  
194 transmembrane helix 1 (motif 1A; RxxhaxxfE, where upper case residues are conserved in  
195 more than 90% of proteins and lower case residues in at least 65% of proteins) is very similar  
196 to that in transmembrane helix 3 (motif 1B; RxxHaxxFe) (Fig. 1B and 1C), and the motif in  
197 transmembrane helix 2 (motif 2A, WNxxy/fNxxFd) is very similar to that in transmembrane  
198 helix 4 (motif 2B; Ytxxf/ynwxyD) (Fig.s 1D and 1E). The notable features of the sequence  
199 motifs in helices 1 and 3 are the membrane-embedded glutamate residue (universally  
200 conserved in helix 1), and histidine and arginine residues at the membrane boundary. The  
201 motifs found in helices 2 and 4 notably contain several aromatic residues along one helical  
202 face adjacent to polar asparagine residues, and an aspartate residue at the membrane boundary  
203 (universally conserved in helix 4) (Fig. 1A).

204 Based on the distribution of charged residues within the loop regions, the N- and C-  
205 termini of most PACE family proteins are predicted to lie within the cytoplasm, but this is yet  
206 to be experimentally tested (Fig. 1). Some PACE family homologs, primarily from  
207 *Acetobacter*, contain predicted N-terminal signal sequences, suggesting that the N-terminus is  
208 moved across the cytoplasmic membrane and that they may exist in an alternative topology,  
209 e.g. APA01\_04520 and APO\_1949 from *A. pasteurianus* IFO 3283-01 and *A. pomorum*  
210 DM001, respectively. Representatives of these proteins have been expressed in *E. coli*, but as  
211 yet, no resistance or transport functions have been identified (Hassan et al., unpublished).  
212 These proteins may be part of a separate protein subfamily from those that mediate drug  
213 resistance.

## 214 **5.Conservation of PACE family genes**

215 PACE family proteins are typically highly conserved in the genome of the bacterial  
216 species in which they are found. For example, genes encoding three different PACE proteins  
217 have been identified in the *A. baumannii* pan-genome (based on the genomes of 623 strains)  
218 [7]. Of these, two were conserved in 100% or close to 100% of the strains and can be  
219 considered to be part of the core genome. The third gene was found in only two strains and is  
220 part of the accessory genome. Similar to *A. baumannii*, *Pseudomonas aeruginosa* isolates  
221 have two PACE proteins encoded in the core genome and one in the accessory genome, which  
222 is found in only a few strains, and *B. cenocepacia* strains encode three PACE pumps in their  
223 core genome [7]. This high level of conservation suggests that PACE pumps are acquired  
224 vertically and have been maintained in their host species since their divergence from related  
225 organisms. They are thus likely to have an important core function that may be unrelated to  
226 drug resistance. Indeed, the biocides that are recognised by PACE family pumps have only  
227 been present in the environment for 50-100 years, and are therefore very unlikely to be the  
228 physiological substrates of these proteins.

229 In contrast to the species described above, *E. coli* do not encode PACE pumps in their  
230 core genomes; four different genes encoding PACE homologs were found among the  
231 genomes of 1986 sequenced *E. coli* strains, but these were each found in 0.2% of strains or  
232 less [7]. These accessory genes are likely to move between related species on mobile genetic  
233 elements. However, there is as yet no strong evidence for how these genes are mobilised.

## 234 **6. Evolution of the PACE family**

235 The conservation of sequence motifs between the N- and C-terminal halves of PACE  
236 proteins suggests that these proteins may have evolved by a duplication event of an ancestral  
237 single BTP domain protein. To investigate this further, the N- and C-terminal BTP domains  
238 were compared between 47 diverse PACE family proteins (Supplemental Fig. S5). The level  
239 of amino acid identity between the N- and C-terminal BTP domains in these proteins ranged

240 from 6.6% to 33.3% (mean 23.3%). The presence of such high levels of sequence identity  
241 between the N- and C-terminal BTP domains across diverse PACE family proteins suggests  
242 that these proteins may not have diverged significantly since the occurrence of the duplication  
243 event(s). Along with the distribution of these proteins almost exclusively within the  
244 Proteobacteria, and their likely vertical acquisition, due to their presence on the core genome,  
245 this may suggest that this protein family is relatively young compared to other families of  
246 transport proteins, which show lower levels of sequence conservation between domains that  
247 are thought to have arisen via duplication [21].

248 To further examine the evolution of PACE family proteins, the levels of sequence  
249 identity between the N-terminal and C-terminal BTP domains of different PACE proteins  
250 were determined. It was found that the N-terminal BTP domains of PACE family proteins  
251 almost always have higher identity to the N-terminal BTP domains of other PACE proteins  
252 than they do to their own C-terminal BTP domain, or the C-terminal BTP domain of other  
253 PACE family pumps (Supplemental Fig. S5). This suggests that a BTP domain duplication  
254 event occurred only once in an ancestral gene, and that there is little or no recombination  
255 between the N- and C-terminal BTP domains in individual strains. The C-terminal BTP  
256 domains of different PACE pumps typically show even higher levels of sequence identity  
257 than the N-terminal domains (Supplemental Fig. S5). The high conservation of sequence  
258 within the C-terminal domain of different proteins may reflect the involvement of the C-  
259 terminal domain in a core part of the functional mechanism, whereas the N-terminal domain  
260 may play a bigger role in substrate recognition.

## 261 **7. Concluding remarks**

262 The PACE family of transport proteins is one of two transporter families discovered  
263 only recently to mediate drug efflux. From currently available analyses, PACE family  
264 proteins display somewhat restricted drug substrate recognition profiles, which include

265 primarily synthetic biocides such as chlorhexidine and acriflavine, rather than the multitudes  
266 of diverse antibiotics and biocides recognised by transport proteins from families such as the  
267 RND superfamily. This may be a primary reason for the family being only recently identified,  
268 15 years after the first descriptions of MATE family pumps [22, 23]. However, PACE  
269 proteins are highly conserved in a range of opportunistic Gram-negative pathogens, including  
270 *A. baumannii*, *P. aeruginosa*, *B. cenocepacia* and *Klebsiella pneumoniae*, and in serious  
271 human pathogens such as *Yersinia pestis*, *Francisella tularensis* and *Burkholderia*  
272 *pseudomallei*. Therefore, the role of these proteins in drug resistance warrants future  
273 investigation.

274 As mentioned above, the drug recognition profile of PACE pumps primarily includes  
275 synthetic biocides, most of which have only been in the environment for 50-100 years.  
276 However, genes encoding homologous PACE family proteins are found in the core genomes  
277 of bacterial genera that diverged much earlier than this, hundreds of millions of years ago.  
278 Therefore, these proteins are likely to mediate an important core function and may have  
279 common physiological substrates that are yet to be described. The importance of PACE  
280 family proteins is likely to extend beyond an apparently fortuitous role in drug resistance.

## 281 **Acknowledgements**

282 Parts of this work were supported by Project Grants from the National Health and  
283 Medical Research Council of Australia to ITP, KAH and PJFH (GNT1060895 and  
284 GNT1120298), a grant from Macquarie University to KAH and LDHE (9201401563) and a  
285 grant from the BBSRC to AG (104399). KAH thanks the EU for the award of a Marie  
286 Skłodowska-Curie Research Fellowship (706499). PJFH thanks the Leverhulme Trust for the  
287 award of an Emeritus Fellowship (EM-2014-045). CLC thanks the BBSRC for support  
288 through a White Rose Research Experience Placement award.

289

290 **References**

- 291 [1] Du D, van Veen HW, Murakami S, Pos KM, Luisi BF. Structure, mechanism and  
292 cooperation of bacterial multidrug transporters. *Curr Opin Struct Biol* 2015;33:76-91.
- 293 [2] Hassan KA, Jackson SM, Penesyan A, Patching SG, Tetu SG, Eijkelkamp BA, et al.  
294 Transcriptomic and biochemical analyses identify a family of chlorhexidine efflux proteins.  
295 *Proc Natl Acad Sci USA* 2013;110:20254-9.
- 296 [3] Hassan KA, Li Q, Henderson PJF, Paulsen IT. Homologs of the *Acinetobacter baumannii*  
297 AceI Transporter Represent a New Family of Bacterial Multidrug Efflux Systems. *mBio*  
298 2015;6:e01982-14.
- 299 [4] Su CC, Bolla JR, Kumar N, Radhakrishnan A, Long F, Delmar JA, et al. Structure and  
300 function of *Neisseria gonorrhoeae* MtrF illuminates a class of antimetabolite efflux pumps.  
301 *Cell Rep* 2015;11:61-70.
- 302 [5] Grkovic S, Brown MH, Skurray RA. Regulation of bacterial drug export systems.  
303 *Microbiology and Molecular Biology Reviews* 2002;66:671-701.
- 304 [6] Andersson DI, Levin BR. The biological cost of antibiotic resistance. *Current Opinion in*  
305 *Microbiology* 1999;2:489-93.
- 306 [7] Hassan KA, Elbourne LD, Li L, Gamage HK, Liu Q, Jackson SM, et al. An ace up their  
307 sleeve: a transcriptomic approach exposes the AceI efflux protein of *Acinetobacter baumannii*  
308 and reveals the drug efflux potential hidden in many microbial pathogens. *Front Microbiol*  
309 2015;6:333.
- 310 [8] World Health Organization. Global priority list of antibiotic-resistant bacteria to guide  
311 research, discovery, and development of new antibiotics. Geneva, 2017.

- 312 [9] Tucker AT, Nowicki EM, Boll JM, Knauf GA, Burdis NC, Trent MS, et al. Defining  
313 gene-phenotype relationships in *Acinetobacter baumannii* through one-step chromosomal  
314 gene inactivation. *mBio* 2014;5:e01313-14.
- 315 [10] Nde CW, Jang HJ, Toghrol F, Bentley WE. Global transcriptomic response of  
316 *Pseudomonas aeruginosa* to chlorhexidine diacetate. *Environ Sci Technol* 2009;43:8406-15.
- 317 [11] Coenye T, Van Acker H, Peeters E, Sass A, Buroni S, Riccardi G, et al. Molecular  
318 mechanisms of chlorhexidine tolerance in *Burkholderia cenocepacia* biofilms. *Antimicrob*  
319 *Agents Chemother* 2011;55:1912-9.
- 320 [12] Turner RJ, Taylor DE, Weiner JH. Expression of *Escherichia coli* TehA gives resistance  
321 to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps.  
322 *Antimicrob Agents Chemother* 1997;41:440-4.
- 323 [13] Blair JM, Piddock LJ. How to Measure Export via Bacterial Multidrug Resistance Efflux  
324 Pumps. *mBio* 2016;7:e00840-16.
- 325 [14] Saier MH, Jr., Reddy VS, Tsu BV, Ahmed MS, Li C, Moreno-Hagelsieb G. The  
326 Transporter Classification Database (TCDB): recent advances. *Nucleic Acids Res*  
327 2016;44:D372-9.
- 328 [15] Elbourne LD, Tetu SG, Hassan KA, Paulsen IT. TransportDB 2.0: a database for  
329 exploring membrane transporters in sequenced genomes from all domains of life. *Nucleic*  
330 *Acids Res* 2017;45:D320-D4.
- 331 [16] Finn RD, Coghill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, et al. The Pfam  
332 protein families database: towards a more sustainable future. *Nucleic Acids Res*  
333 2016;44:D279-85.

- 334 [17] Lee SC, Knowles TJ, Postis VL, Jamshad M, Parslow RA, Lin YP, et al. A method for  
335 detergent-free isolation of membrane proteins in their local lipid environment. *Nat Protoc*  
336 2016;11:1149-62.
- 337 [18] Fluman N, Ryan CM, Whitelegge JP, Bibi E. Dissection of mechanistic principles of a  
338 secondary multidrug efflux protein. *Mol Cell* 2012;47:777-87.
- 339 [19] Soskine M, Adam Y, Schuldiner S. Direct evidence for substrate-induced proton release  
340 in detergent-solubilized EmrE, a multidrug transporter. *J Biol Chem* 2004;279:9951-5.
- 341 [20] Radchenko M, Symersky J, Nie R, Lu M. Structural basis for the blockade of MATE  
342 multidrug efflux pumps. *Nat Commun* 2015;6:7995.
- 343 [21] Saier MH, Jr. Tracing pathways of transport protein evolution. *Mol Microbiol*  
344 2003;48:1145-56.
- 345 [22] Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, et al. NorM, a  
346 putative multidrug efflux protein, of *Vibrio parahaemolyticus* and its homolog in *Escherichia*  
347 *coli*. *Antimicrob Agents Chemother* 1998;42:1778-82.
- 348 [23] Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype  
349 of a new family of transporters. *Mol Microbiol* 1999;31:394-6.
- 350 [24] Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: a sequence logo generator.  
351 *Genome Res* 2004;14:1188-90.
- 352 [25] Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al.  
353 Clustal W and Clustal X version 2.0. *Bioinformatics* 2007;23:2947-8.
- 354 [26] Okonechnikov K, Golosova O, Fursov M, team U. Unipro UGENE: a unified  
355 bioinformatics toolkit. *Bioinformatics* 2012;28:1166-7.



- 356 [27] Ward A, Sanderson NM, O'Reilly J, Rutherford NG, Poolman B, Henderson PJF. The  
357 amplified expression, identification, purification, assay, and properties of hexahistidine-  
358 tagged bacterial membrane transport proteins. in: SA Baldwin (Ed.), Membrane transport: a  
359 practical approach, Oxford University Press, Oxford, 2000, pp. 141-66.
- 360 [28] Stark MJ. Multicopy expression vectors carrying the *lac* repressor gene for regulated  
361 high-level expression of genes in *Escherichia coli*. *Gene* 1987;51:255-67.
- 362 [29] Campanella JJ, Bitincka L, Smalley J. MatGAT: an application that generates  
363 similarity/identity matrices using protein or DNA sequences. *BMC Bioinformatics* 2003;4:29.
- 364

365 **Figure legends**

366 Fig. 1. Predicted transmembrane topology and conserved amino acid sequence motifs present  
367 in PACE family proteins. An amino acid sequence alignment of 47 diverse PACE family  
368 proteins (Supplemental Fig. S1), encoded by a broad range of hosts, was used to identify  
369 amino acid sequence motifs that are conserved across the family. (A) Predicted topology of  
370 PACE family proteins. Upper case characters are conserved in greater than 90% of protein  
371 sequences and characters in lower case are conserved in greater than 65% but fewer than 90%  
372 of the aligned protein sequences. Conserved residues are coloured (red: negatively charged,  
373 blue: positively charged, orange: aromatic, black: others). The similar amino acid sequence  
374 motifs in helices 1 and 3 (1A and 1B, respectively) are surrounded by purple lines, and the  
375 similar sequence motifs in helices 2 and 4 (2A and 2B, respectively) are surrounded by green  
376 lines. (B-E) Sequence logos, made using WebLogo 3 [24], showing conservation of amino  
377 acid residues in the four sequence motifs identified in PACE proteins; error bars show an  
378 approximate Bayesian 95% confidence interval [24].

379 Fig. 2. Acriflavine transport mediated by PACE family proteins encoded by the human  
380 pathogen *Burkholderia cenocepacia* HI2424. A) Transport experiments performed using *E.*  
381 *coli* OmniMax cells expressing the proteins of interest, essentially as described previously [3].  
382 The cells were preloaded with 5  $\mu$ M acriflavine in the presence of 10  $\mu$ M CCCP. The cells  
383 were washed and re-energised using glucose at the point marked with an arrow and transport  
384 monitored fluorimetrically. Acriflavine fluorescence is quenched when it is intercalated into  
385 nucleic acids. Therefore, its transport out of the cell is associated with an increase in  
386 fluorescence. B) Western blot performed on the cells used in the assay, probed using His-  
387 Probe-HRP. The *B. cenocepacia* HI2424 PACE family proteins Bcen2424\_2356 and  
388 Bcen2424\_5347 were expressed at easily detectable levels after the 1-h induction used for  
389 this assay. Bcen2424\_2356 promoted the rapid efflux of acriflavine, whereas Bcen2424\_5347

390 did not promote acriflavine transport above background. The third PACE family protein  
391 encoded by *B. cenocepacia* HI2424, Bcen2424\_5167 was not expressed and was excluded  
392 from the figure. Bcen2424\_5167 and Bcen2424\_5347 are phylogenetically distinct from  
393 Bcen2424\_2356. Error bars show the standard deviation of three replicate experiments.

394

ACCEPTED MANUSCRIPT

### 395 Supplemental figure legends

396 Fig. S1. Amino acid sequence alignment of 47 diverse PACE family proteins. The sequences  
397 are named by locus tag or NCBI protein accession. Sequences were obtained from the NCBI  
398 genomes database and aligned using ClustalX [25]. The alignment is coloured according to  
399 the level of amino acid sequence conservation at each position. Colours were added using the  
400 UGENE toolkit [26].

401 Fig. S2. Kinetic response curves paralleling bacterial growth for Biolog phenotype microarray  
402 antimicrobial tests in which the pTTQ18-Bcen2424\_2356 plasmid facilitated a growth  
403 advantage. Curves for *E. coli* BL21 cells carrying pTTQ18 are shown in red, curves for BL21  
404 cells carrying pTTQ18-Bcen2424\_2356 are shown in green and regions of overlap in the  
405 response curves of these two strains are shown in yellow. The tests were conducted according  
406 to the manufacturer's instructions in the presence of 0.05 mM IPTG to promote expression of  
407 the cloned Bcen2424\_2356 gene. The curves depict the color intensity of a redox-active dye  
408 (y axis) over time (x axis; 30 h). (A) plate PM12, well E12 (benzethonium chloride) (B) plate  
409 PM14, well A3 (acriflavine), (C) plate PM14, well B3 (9-aminoacridine), (D) plate PM15,  
410 well E11 (methyl viologen), (E) plate PM18, well G7 (3,5-diamino-1,2,4-triazole  
411 [guanazole]), (F) plate PM18, well H12 (plumbagin), (G) plate PM19, well C4  
412 (chlorhexidine).

413 Fig. S3. Putative substrates of PACE family proteins identified using whole cell transport  
414 experiments (chlorhexidine, acriflavine), conventional minimum inhibitory concentration  
415 analyses, (chlorhexidine, acriflavine, benzalkonium, dequalinium) and/or higher throughput  
416 resistance tests using the Biolog Phenotype Microarray system (chlorhexidine, acriflavine,  
417 benzethonium, 9-aminoacridine, methyl viologen, guanazole, plumbagin, domiphen). The  
418 chemical structures were obtained from the NCBI PubChem database and viewed using the  
419 web-based MolView tool ([molview.org](http://molview.org)).

420 Fig. S4. Solubilisation and purification of the *Ferrimonas balearica* DSM 9799 PACE family  
421 protein, Fbal\_3166 [3], using styrene maleic acid co-polymer and Ni-affinity purification.  
422 Fbal\_3166 protein was overexpressed in *E. coli* BL21 cells grown in a 30 L fermenter using  
423 the pTTQ18 expression system [27, 28]. Styrene maleic acid co-polymer preparation,  
424 membrane solubilisation and Ni-affinity purification were performed as previously described  
425 [17]. Samples consisting of solubilised membrane proteins (lane A), proteins that did not bind  
426 to the Ni-affinity column (lane B) and purified Fbal\_3166 (lane C) were run on a 15% SDS-  
427 PAGE gel and stained with Coomassie brilliant blue R-250. The size (kDa) of co-migrated  
428 soluble molecular weight markers is shown on the left side of the gel.

429 Fig. S5. Pairwise comparisons of the individual BTP domains in 47 diverse PACE family  
430 proteins. The amino acid sequences of the separated domains were analysed using the MatGat  
431 tool [29] to determine the percent identity between each domain. The amino acid sequence  
432 identities of each pair of domains are shown in the pairwise distribution plot and coloured  
433 according to percent identity (red: low identity, yellow: intermediate identity, and green: high  
434 identity). The top left region of the plot shows comparisons between the N-terminal BTP  
435 domains of different proteins and the bottom right region of the plot shows comparisons  
436 between the C-terminal BTP domains of different proteins. The central boxed region of the  
437 plot represents comparisons between the N-terminal domains and C-terminal domains of the  
438 proteins. The small boxes within this region highlight comparisons between the N- and C-  
439 terminal domains of the same protein.

440



